Nalmefene hydrochloride, a naltrexone analogue, is an inverse agonist at the μ-opioid receptor (MOR) and as a weak partial agonist at the κ-opioid receptor. Nalmefene hydrochloride is used as treatment for addiction.
naltrexone analogue; inverse agonist at the μ-opioid receptor (MOR) and as a weak partial agonist at the κ-opioid receptor
Frontiers in pharmacology, 10, 1087-1087 (2019-10-16)
Nalmefene is approved for as-needed pharmacological treatment in alcohol use disorder (AUD) by the European Medicines Agency. While the cellular effects of nalmefene have been thoroughly investigated, data are very limited on how this agent influences neural signals associated with
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 26(12), 1941-1949 (2016-11-16)
Nalmefene, a mu- and delta-opioid receptor (MOR, DOR) antagonist and a partial kappa-opioid receptor (KOR) agonist, is approved in the European Union and other countries for the reduction of alcohol consumption in alcohol dependent patients with a high drinking risk
British journal of pharmacology, 173(16), 2490-2505 (2016-05-31)
The opioid antagonist nalmefene (selincro®) was approved for alcohol-related disorders by the European Medicines Agency in 2013. However, there have been no studies regarding the effectiveness of nalmefene when alcohol is used in combination with cocaine. Using operant alcohol self-administration
